Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky.

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.

Ocugen is developing OCU410 as a 1-time gene therapy for the treatment of geographic atrophy. It utilizes an AAV delivery platform for the retinal delivery of the ROR Related Orphan Receptor A gene.

Two novel reading speed metrics may better indicate functional decline in geographic atrophy than 2 more commonly-used methods. In patients with geographic atrophy secondary to age-related macular ...

Geographic atrophy is a subtype of advanced age-related macular degeneration (AMD). It causes blind spots in the center of vision and a permanent loss of visual sharpness. AMD progresses through ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy ... reviewed at the CHMP's October meeting, but was left ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Geographic atrophy: semantic considerations and literature ... for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology 2018; 125: ...

Geographic atrophy (GA) is the non-neovascular form of late age-related macular degeneration ... Moreover, in patients considered for enrolment, presence of GA was further confirmed by spectral-domain ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD ...